Antihypertensive Therapy in the Acute Phase of Lacunar Infarcts
- PMID: 30243025
- PMCID: PMC6166525
- DOI: 10.12659/MSM.910183
Antihypertensive Therapy in the Acute Phase of Lacunar Infarcts
Abstract
BACKGROUND The optimal medical regimen for managing hypertension during acute phase of lacunar infarcts has not yet been clarified in real world setting. The aim of this study was to evaluate blood pressure lowering regimens on neurological progression and clinical outcomes during the acute phase of lacunar infarcts. MATERIAL AND METHODS For this study, 411 patients with first-episode lacunar infarcts and hypertension within 24 hours of symptom onset were included. All patients received antihypertension therapies, with different regimens, as well as routine medication during first 7 days after onset. There were 6 proposed antihypertensive treatments: calcium channel blockers (CCB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), β-blocker (β-B), and diuretic drug (DD) alone or in combination. Neurological progression was defined as worsening by ≥1 point in the National Institute of Health Stroke Scale (NIHSS) for motor function. The outcome was assessed using the modified Rankin Scale (mRS): favorable outcome (mRS of 0-1) or unfavorable outcome (mRS 2-5). RESULTS Logistic regression analysis showed that combination therapy with CCB, ACEI/ARB, and β-B exhibited the lowest risk of deterioration (OR=0.48, P=0.019) and unfavorable outcomes (OR=0.50, P=0.022). Similarly, combination therapy with CCB, ACEI/ARB, and DD exhibited lower risk of deterioration (OR=0.63, P=0.033) and unfavorable outcome (OR=0.77, P=0.042) at 3 months. CONCLUSIONS Rational blood pressure lowering was beneficial to the functional outcomes of patients during acute phase of lacunar infarcts, and combination therapy was better than mono-drug therapy.
Conflict of interest statement
None.
Similar articles
-
Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort.JAMA Netw Open. 2022 Mar 1;5(3):e223877. doi: 10.1001/jamanetworkopen.2022.3877. JAMA Netw Open. 2022. PMID: 35323951 Free PMC article.
-
Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.J Am Pharm Assoc (2003). 2010 Sep-Oct;50(5):e116-25. doi: 10.1331/JAPhA.2010.09234. J Am Pharm Assoc (2003). 2010. PMID: 20833609 Review.
-
Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.Chin Med J (Engl). 2016 Mar 5;129(5):562-9. doi: 10.4103/0366-6999.176987. Chin Med J (Engl). 2016. PMID: 26904991 Free PMC article.
-
[Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].Ann Cardiol Angeiol (Paris). 2012 Jun;61(3):218-23. doi: 10.1016/j.ancard.2012.05.002. Epub 2012 May 23. Ann Cardiol Angeiol (Paris). 2012. PMID: 22695025 French.
-
Antihypertensive drugs and fibrinolytic function.Am J Hypertens. 2006 Dec;19(12):1293-9. doi: 10.1016/j.amjhyper.2006.04.013. Am J Hypertens. 2006. PMID: 17161777 Review.
Cited by
-
Bioinformatic Exploration of Circulating microRNAs Related to Functional Outcomes in Patients With Acute Ischemic Stroke: An Exploratory Prospective Study.Cureus. 2024 Aug 22;16(8):e67476. doi: 10.7759/cureus.67476. eCollection 2024 Aug. Cureus. 2024. PMID: 39310540 Free PMC article.
-
Functional Disability After Ischemic Stroke: A Community-Based Cross-Sectional Study in Shanghai, China.Front Neurol. 2021 Aug 26;12:649088. doi: 10.3389/fneur.2021.649088. eCollection 2021. Front Neurol. 2021. PMID: 34512499 Free PMC article.
References
-
- Zhao D, Liu J, Wang W, et al. Epidemiological transition of stroke in China: Twenty-one-year observational study from the Sino-Monica-Beijing project. Stroke. 2008;39:1668–74. - PubMed
-
- Sandset EC, Murray GD, Bath PM, et al. Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. Stroke. 2012;43:2108–14. - PubMed
-
- Hankey GJ. Lowering blood pressure in acute stroke: The SCAST trial. Lancet. 2011;377:696–98. - PubMed
-
- Sandset EC. Blood pressure in acute stroke. Lancet Neurol. 2014;13:342–43. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources